Absence of JAK2 V617F mutation in thalassemia intermedia patients

Molecular Biology Reports

Volumn 36, Issue 6, 2009, Pages 1555-1557

  Taher, Ali ^a   Shammaa, Dina ^a   Bazarbachi, Ali ^a   Itani, Doha ^a   Zaatari, Ghazi ^a   Greige, Layal ^a   Otrock, Zaher K ^a   Mahfouz, Rami A R ^a  

^a AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

Author keywords

Intermedia; JAK2; Mutation; Thalassemia; V617F

Indexed keywords

JANUS KINASE 2; PHENYLALANINE; VALINE;

ARTICLE; BETA THALASSEMIA; CLINICAL ARTICLE; ENZYME ASSAY; FEMALE; GENE MUTATION; GENETIC ASSOCIATION; HUMAN; LEBANON; MALE; POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; THALASSEMIA INTERMEDIA;

DNA MUTATIONAL ANALYSIS; GENE FREQUENCY; HUMANS; JANUS KINASE 2; LEBANON; MUTATION, MISSENSE; POLYMERASE CHAIN REACTION; THALASSEMIA;

EID: 67651092220     PISSN: 03014851     EISSN: 15734978     Source Type: Journal    
DOI: 10.1007/s11033-008-9350-0     Document Type: Article

References (23)

1. E Komura H Chagraoui V Mansat de Mas B Blanchet P de Sepulveda F Larbret J Larghero M Tulliez N Debili W Vainchenker S Giraudier 2003 Spontaneous STAT5 activation induces growth factor independence in idiopathic myelofibrosis: possible relationship with FKBP51 overexpression Exp Hematol 31 622 630
2. V Ugo C Marzac I Teyssandier F Larbret Y Lécluse N Debili W Vainchenker N Casadevall 2004 Multiple signaling pathways are involved in erythropoietin-independent differentiation of erythroid progenitors in polycythemia Vera Exp Hematol 32 179 187
3. P Saharinen K Takaluoma O Silvennoinen 2000 Regulation of the JAK2 tyrosine kinase by its pseudokinase domain Mol Cell Biol 20 3387 3395
4. R Zhao S Xing Z Li X Fu Q Li SB Krantz ZJ Zhao 2005 Identification of an acquired JAK2 mutation in polycythemia Vera J Biol Chem 280 22788 22792
5. R Kralovics F Passamonti AS Buser SS Teo R Tiedt JR Passweg A Tichelli M Cazzola RC Skoda 2005 A gain-of-function mutation of JAK2 in myeloproliferative disorders N Engl J Med 352 1779 1790 (Pubitemid 40570926)
6. BA Witthuhn FW Quelle O Silvennoinen T Yi B Tang O Miura JN Ihle 1993 JAK2 associates with the erythropoietin receptor and is tyrosine phosphorylated and activated following stimulation with erythropoietin Cell 74 227 236
7. M Socolovsky AE Fallon S Wang C Brugnara HF Lodish 1999 Fetal anemia and apoptosis of red cell progenitors in STAT5A-/-5B-/- mice: a direct role for STAT5 in Bcl-X(L) induction Cell 98 181 191
8. JH Myklebust HK Blomhoff LS Rusten T Stokke EB Smeland 2002 Activation of phosphatidylinositol 3-kinase is important for erythropoietin-induced erythropoiesis from CD34 (+) hematopoietic progenitor cells Exp Hematol 30 990 1000
9. SB Krantz 1991 Erythropoietin Blood 77 419 434
10. AD D'Andrea HF Lodish GG Wong 1989 Expression cloning of the murine erythropoietin receptor Cell 57 277 285
11. EJ Baxter LM Scott PJ Campbell C East N Fourouclas S Swanton GS Vassiliou AJ Bench EM Boyd N Curtin MA Scott WN Erber AR Green Cancer Genome Project 2005 Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders Lancet 365 1054 1061
12. RL Levine C Belisle M Wadleigh D Zahrieh S Lee P Chagnon DG Gilliland L Busque 2006 X-inactivation-based clonality analysis and quantitative JAK2 V617F assessment reveal a strong association between clonality and JAK2 V617F in PV but not ET/MMM, and identifies a subset of JAK2 V617F-negative ET and MMM patients with clonal hematopoiesis Blood 107 4139 4141
13. PJ Campbell M Griesshammer K Döhner H Döhner R Kusec HC Hasselbalch TS Larsen N Pallisgaard S Giraudier MC Le Bousse-Kerdilès C Desterke B Guerton B Dupriez D Bordessoule P Fenaux JJ Kiladjian JF Viallard J Brière CN Harrison AR Green JT Reilly 2006 V617F mutation in JAK2 is associated with poorer survival in idiopathic myelofibrosis Blood 107 2098 2100
14. AV Jones S Kreil K Zoi K Waghorn C Curtis L Zhang J Score R Seear AJ Chase FH Grand H White C Zoi D Loukopoulos E Terpos EC Vervessou B Schultheis M Emig T Ernst E Lengfelder R Hehlmann A Hochhaus D Oscier RT Silver A Reiter NC Cross 2005 Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders Blood 106 2162 2168
15. DP Steensma GW Dewald TL Lasho HL Powell RF McClure RL Levine DG Gilliland A Tefferi 2005 The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both "atypical" myeloproliferative disorders and myelodysplastic syndromes Blood 106 1207 1209
16. LM Scott PJ Campbell EJ Baxter T Todd P Stephens S Edkins R Wooster MR Stratton PA Futreal AR Green 2005 The V617F JAK2 mutation is uncommon in cancers and in myeloid malignancies other than the classic myeloproliferative disorders Blood 106 2920 2921
17. RL Levine M Loriaux BJ Huntly ML Loh M Beran E Stoffregen R Berger JJ Clark SG Willis KT Nguyen NJ Flores E Estey N Gattermann S Armstrong AT Look JD Griffin OA Bernard MC Heinrich DG Gilliland B Druker MW Deininger 2005 The JAK2 V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia Blood 106 3377 3379
18. J Jelinek Y Oki V Gharibyan C Bueso-Ramos JT Prchal S Verstovsek M Beran E Estey HM Kantarjian JP Issa 2005 JAK2 mutation 1849G>T is rare in acute leukemia's but can be found in CMML, Philadelphia chromosome-negative CML, and megakaryocytic leukemia Blood 106 3370 3373
19. S Fröhling DB Lipka S Kayser C Scholl RF Schlenk H Döhner DG Gilliland RL Levine K Döhner 2006 Rare occurrence of the JAK2 V617F mutation in AML subtypes M5, M6, and M7 Blood 107 1242 1243
20. A Aessopos M Kati J Meletis 2007 Thalassemia intermedia today: should patients regularly receive transfusions? Transfusion 47 792 800
21. NF Olivieri 1999 The beta-thalassemias N Engl J Med 341 99 109
22. C Camaschella MD Cappellini 1995 Thalassemia intermedia Haematologica 80 58 68
23. PJ Campbell LM Scott G Buck K Wheatley CL East JT Marsden A Duffy EM Boyd AJ Bench MA Scott GS Vassiliou DW Milligan SR Smith WN Erber D Bareford BS Wilkins JT Reilly CN Harrison AR Green United Kingdom Myeloproliferative Disorders Study Group Medical Research Council Adult Leukaemia Working Party Australasian Leukaemia and Lymphoma Group 2005 Definition of subtypes of essential thrombocythemia and relation to polycythemia Vera based on JAK2 V617F mutation status: a prospective study Lancet 366 1945 1953